Emtricitabine/rilpivirine/tenofovir

Emtricitabine/rilpivirine/tenofovir, a wɔtɔn wɔ din Complera mu no yɛ nnuru a wɔde di HIV/AIDS ho dwuma. Gilead Sciences ne Johnson & Johnson's Tibotec na wɔyɛɛ aduru no, na US Food and Drug Administration (FDA) penee so wɔ August 2011, na European Medicines Agency nso penee so wɔ November 2011, maa ayarefo a wonnyaa HIV ho ayaresa da. Wonya no te sɛ kuruwa biako a wotwa no da biara.

 Nnuruyɛ dwumadie 
Wɔde emtricitabine/rilpivirine/tenofovir di dwuma de sa HIV- 1 yareɛ wɔ mpanimfoɔ a wonnii HIV- 1 nnuru da (berɛ a yareɛ mmoawa no antumi annye nnuro a ɛko tia HIV- 1 yi ano) na wonni HIV- 1 RNA a ɛboro 100,000 wɔ mL biara mu wɔ wɔn mogya mu ( "viral load")

 Baabi a menyaa mmoa firiiɛ